FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024294177> ?p ?o ?g. }

• W2024294177 endingPage "7" @default.
• W2024294177 startingPage "1" @default.
• W2024294177 abstract "<i>Objective:</i> This dose-escalation study of a combination of docetaxel, cisplatin and S-1 investigated the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), recommended dose (RD) and antitumor activity in advanced gastric cancer. <i>Patients and Methods:</i> Patients received docetaxel (40 mg/m²), cisplatin (DIV on day 1) and S-1 (40 mg/m² p.o., twice daily, on days 1–14 every 28 days). The starting dose of cisplatin was 60 mg/m² (level 1); the dose was escalated to 70 (level 2) and 80 mg/m² (level 3) in a stepwise fashion. <i>Results:</i> Fourteen patients were enrolled. The MTD of cisplatin was 80 mg/m² (level 3). DLT was grade 3 diarrhea, febrile neutropenia and delayed resumption of treatment. The RD of cisplatin was considered to be 70 mg/m² (level 2). DLT was liver dysfunction, occurring in only 1 patient at level 2. The response rate was 69.2% (9/13). <i>Conclusions:</i> For combined treatment with docetaxel, cisplatin and S-1 in patients with advanced gastric cancer, RD were docetaxel 40 mg/m², cisplatin 70 mg/m² and S-1 80 mg/m²/day. This regimen yields a high rate of tumor response and can be administered safely. Phase II studies of this regimen are under way." @default.
• W2024294177 created "2016-06-24" @default.
• W2024294177 creator A5033827561 @default.
• W2024294177 creator A5039063528 @default.
• W2024294177 creator A5040745867 @default.
• W2024294177 creator A5056426636 @default.
• W2024294177 creator A5068425977 @default.
• W2024294177 creator A5071422219 @default.
• W2024294177 creator A5075488010 @default.
• W2024294177 creator A5078734873 @default.
• W2024294177 creator A5090273056 @default.
• W2024294177 creator A5090659723 @default.
• W2024294177 date "2008-01-01" @default.
• W2024294177 modified "2023-10-16" @default.
• W2024294177 title "A Multicenter, Phase I Dose-Escalating Study of Docetaxel, Cisplatin and S-1 for Advanced Gastric Cancer (KDOG0601)" @default.
• W2024294177 cites W1883066466 @default.
• W2024294177 cites W1940165440 @default.
• W2024294177 cites W1955744924 @default.
• W2024294177 cites W1973175225 @default.
• W2024294177 cites W1974734959 @default.
• W2024294177 cites W1992103975 @default.
• W2024294177 cites W2008575122 @default.
• W2024294177 cites W2018619890 @default.
• W2024294177 cites W2020830322 @default.
• W2024294177 cites W2027678619 @default.
• W2024294177 cites W2029389980 @default.
• W2024294177 cites W2039081285 @default.
• W2024294177 cites W2077902459 @default.
• W2024294177 cites W2086737079 @default.
• W2024294177 cites W2106787323 @default.
• W2024294177 cites W2119923371 @default.
• W2024294177 cites W2122866527 @default.
• W2024294177 cites W2131926022 @default.
• W2024294177 cites W2133127344 @default.
• W2024294177 cites W2152256906 @default.
• W2024294177 cites W2158387151 @default.
• W2024294177 cites W2161990928 @default.
• W2024294177 cites W2170346929 @default.
• W2024294177 cites W2171075804 @default.
• W2024294177 cites W2185943375 @default.
• W2024294177 cites W2262127979 @default.
• W2024294177 cites W2282932528 @default.
• W2024294177 cites W2404450510 @default.
• W2024294177 cites W2407889194 @default.
• W2024294177 cites W2528428498 @default.
• W2024294177 doi "https://doi.org/10.1159/000151613" @default.
• W2024294177 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18719348" @default.
• W2024294177 hasPublicationYear "2008" @default.
• W2024294177 type Work @default.
• W2024294177 sameAs 2024294177 @default.
• W2024294177 citedByCount "31" @default.
• W2024294177 countsByYear W20242941772012 @default.
• W2024294177 countsByYear W20242941772013 @default.
• W2024294177 countsByYear W20242941772015 @default.
• W2024294177 countsByYear W20242941772016 @default.
• W2024294177 countsByYear W20242941772017 @default.
• W2024294177 countsByYear W20242941772018 @default.
• W2024294177 countsByYear W20242941772019 @default.
• W2024294177 countsByYear W20242941772020 @default.
• W2024294177 countsByYear W20242941772021 @default.
• W2024294177 countsByYear W20242941772022 @default.
• W2024294177 crossrefType "journal-article" @default.
• W2024294177 hasAuthorship W2024294177A5033827561 @default.
• W2024294177 hasAuthorship W2024294177A5039063528 @default.
• W2024294177 hasAuthorship W2024294177A5040745867 @default.
• W2024294177 hasAuthorship W2024294177A5056426636 @default.
• W2024294177 hasAuthorship W2024294177A5068425977 @default.
• W2024294177 hasAuthorship W2024294177A5071422219 @default.
• W2024294177 hasAuthorship W2024294177A5075488010 @default.
• W2024294177 hasAuthorship W2024294177A5078734873 @default.
• W2024294177 hasAuthorship W2024294177A5090273056 @default.
• W2024294177 hasAuthorship W2024294177A5090659723 @default.
• W2024294177 hasConcept C121608353 @default.
• W2024294177 hasConcept C126322002 @default.
• W2024294177 hasConcept C2776694085 @default.
• W2024294177 hasConcept C2777063308 @default.
• W2024294177 hasConcept C2778239845 @default.
• W2024294177 hasConcept C2781190966 @default.
• W2024294177 hasConcept C71924100 @default.
• W2024294177 hasConcept C90924648 @default.
• W2024294177 hasConceptScore W2024294177C121608353 @default.
• W2024294177 hasConceptScore W2024294177C126322002 @default.
• W2024294177 hasConceptScore W2024294177C2776694085 @default.
• W2024294177 hasConceptScore W2024294177C2777063308 @default.
• W2024294177 hasConceptScore W2024294177C2778239845 @default.
• W2024294177 hasConceptScore W2024294177C2781190966 @default.
• W2024294177 hasConceptScore W2024294177C71924100 @default.
• W2024294177 hasConceptScore W2024294177C90924648 @default.
• W2024294177 hasIssue "1-2" @default.
• W2024294177 hasLocation W20242941771 @default.
• W2024294177 hasLocation W20242941772 @default.
• W2024294177 hasOpenAccess W2024294177 @default.
• W2024294177 hasPrimaryLocation W20242941771 @default.
• W2024294177 hasRelatedWork W13394025 @default.
• W2024294177 hasRelatedWork W2358040980 @default.
• W2024294177 hasRelatedWork W2371287473 @default.
• W2024294177 hasRelatedWork W2374947457 @default.
• W2024294177 hasRelatedWork W2378605750 @default.

• next